These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20626398)

  • 1. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
    Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
    J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
    Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
    Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinases in health and disease.
    Ghigo A; Morello F; Perino A; Hirsch E
    Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a role for the p110-alpha isoform of PI3K in skeletal function.
    Grey A; Chaussade C; Empson V; Lin JM; Watson M; O'Sullivan S; Rewcastle G; Naot D; Cornish J; Shepherd P
    Biochem Biophys Res Commun; 2010 Jan; 391(1):564-9. PubMed ID: 19931507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
    Valet C; Severin S; Chicanne G; Laurent PA; Gaits-Iacovoni F; Gratacap MP; Payrastre B
    Adv Biol Regul; 2016 May; 61():33-41. PubMed ID: 26714793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
    Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are class II phosphoinositide 3-kinases potential targets for anticancer therapies?
    Traer CJ; Foster FM; Abraham SM; Fry MJ
    Bull Cancer; 2006 May; 93(5):E53-8. PubMed ID: 16777618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the alpha-isoform of class II phosphoinositide 3-kinase gene expression leads to apoptotic cell death.
    Kang S; Song J; Kang J; Kang H; Lee D; Lee Y; Park D
    Biochem Biophys Res Commun; 2005 Apr; 329(1):6-10. PubMed ID: 15721265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
    Oudit GY; Penninger JM
    Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K signaling in arterial diseases: Non redundant functions of the PI3K isoforms.
    Lupieri A; Smirnova N; Malet N; Gayral S; Laffargue M
    Adv Biol Regul; 2015 Sep; 59():4-18. PubMed ID: 26238239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Rho-kinase inhibitors for cardiovascular medicine.
    Shimokawa H; Rashid M
    Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Fine R; Weis S; Hood J; Demaria A; Soll R; Cheresh D
    Proc Natl Acad Sci U S A; 2006 Dec; 103(52):19866-71. PubMed ID: 17172449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.